Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stake Raised by Wellington Management Group LLP

Wellington Management Group LLP increased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 13.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,964,044 shares of the biopharmaceutical company's stock after acquiring an additional 2,856,101 shares during the quarter. Wellington Management Group LLP owned about 8.02% of Amicus Therapeutics worth $255,936,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Assenagon Asset Management S.A. acquired a new position in Amicus Therapeutics in the 2nd quarter valued at about $8,386,000. M&G Plc boosted its holdings in Amicus Therapeutics by 12.4% in the 2nd quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company's stock valued at $7,485,000 after purchasing an additional 82,728 shares during the last quarter. Fiera Capital Corp boosted its holdings in Amicus Therapeutics by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company's stock valued at $52,382,000 after purchasing an additional 58,113 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Amicus Therapeutics by 51.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company's stock valued at $2,381,000 after purchasing an additional 75,807 shares during the last quarter. Finally, Mutual of America Capital Management LLC raised its stake in shares of Amicus Therapeutics by 24.2% in the 2nd quarter. Mutual of America Capital Management LLC now owns 250,293 shares of the biopharmaceutical company's stock valued at $2,483,000 after acquiring an additional 48,802 shares during the period.

Amicus Therapeutics Trading Up 1.0 %

Shares of FOLD traded up $0.10 during midday trading on Monday, hitting $9.83. 7,813,575 shares of the stock traded hands, compared to its average volume of 2,715,206. The business's 50 day moving average price is $10.59 and its two-hundred day moving average price is $10.61. Amicus Therapeutics, Inc. has a 1-year low of $9.02 and a 1-year high of $14.57. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,901 shares of the business's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $11,083,175. The trade was a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 30,401 shares of company stock valued at $339,363 over the last 90 days. 2.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, November 12th. Jefferies Financial Group began coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They issued a "buy" rating and a $18.00 price objective on the stock. Guggenheim increased their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. StockNews.com cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, December 2nd. Finally, Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $17.63.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.